Chitosan grafted-poly(ethylene glycol) methacrylate nanoparticles as carrier for controlled release of bevacizumab

Savin, Corina-Lenuța; Popa, Marcel; Delaite, Christelle; Costuleanu, Marcel; Costin, D; Peptu, Cătălina Anişoara

doi:10.1016/j.msec.2019.01.036

Cited by 69 publications

(37 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It also showed a controlled drug release for several days, related to the swelling behavior in an aqueous environment. Moreover, it resulted practically non‐toxic, hemocompatible and it had moderate efficacy in the treatment of inflammation induced by lipopolysaccharide and central retinal vein occlusion models in rabbits and high efficacy as an anti‐angiogenic treatment in a model of diabetes in rabbits 118 …”

Section: Nanoparticulate Systems For Bd Delivery Intended For Ocular mentioning

confidence: 99%

Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology

Formica

Alfonso

Palma

2021

Pharmacology Res & Perspec

View full text Add to dashboard Cite

Currently, biological drug therapy for ocular angiogenesis treatment is based on the administration of anti‐VEGF agents via intravitreal route. The molecules approved with this purpose for ocular use include pegaptanib, ranibizumab, and aflibercept, whereas bevacizumab is commonly off‐label used in the clinical practice. The schedule dosage involves repeated intravitreal injections of anti‐VEGF agents to achieve and maintain effective concentrations in retina and choroids, which are administrated as solutions form. In this review article, we describe the features of different anti‐VEGF agents, major challenges for their ocular delivery and the nanoparticles in development as delivery system of them. In this way, several polymeric and lipid nanoparticles are explored to load anti‐VEGF agents with the aim of achieving sustained drug release and thus, minimize the number of intravitreal injections required. The main challenges were focused in the loading the molecules that maintain their bioactivity after their release from nanoparticulate system, followed the evaluation of them through studies of formulation stability, pharmacokinetic, and efficacy in in vitro and in vivo models. The analysis was based on the information published in peer‐reviewed published papers relevant to anti‐VEGF treatments and nanoparticles developed as ocular anti‐VEGF delivery system.

show abstract

Section: Nanoparticulate Systems For Bd Delivery Intended For Ocular mentioning

confidence: 99%

Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology

Formica

Alfonso

Palma

2021

Pharmacology Res & Perspec

View full text Add to dashboard Cite

show abstract

“…The carrier obtained showed nontoxicity and hemocompatibility, and it is considered to be a potential delivery agent for the controlled release of Bevacizumab, an ophthalmic drug. The other benefits of this carrier are a lower administered dose, prolonged release, the effectiveness of local delivery, and targeted administration through local injection next to the retina [52].…”

Section: Biopolymers and Biopolymer Nanocompositesmentioning

confidence: 99%

Polymers and Polymer Nanocomposites for Cancer Therapy

Feldman

2019

Applied Sciences

View full text Add to dashboard Cite

Synthetic polymers, biopolymers, and their nanocomposites are being studied, and some of them are already used in different medical areas. Among the synthetic ones that can be mentioned are polyolefins, fluorinated polymers, polyesters, silicones, and others. Biopolymers such as polysaccharides (chitosan, hyaluronic acid, starch, cellulose, alginates) and proteins (silk, fibroin) have also become widely used and investigated for applications in medicine. Besides synthetic polymers and biopolymers, their nanocomposites, which are hybrids formed by a macromolecular matrix and a nanofiller (mineral or organic), have attracted great attention in the last decades in medicine and in other fields due to their outstanding properties. This review covers studies done recently using the polymers, biopolymers, nanocomposites, polymer micelles, nanomicelles, polymer hydrogels, nanogels, polymersomes, and liposomes used in medicine as drugs or drug carriers for cancer therapy and underlines their responses to internal and external stimuli able to make them more active and efficient. They are able to replace conventional cancer drug carriers, with better results. Appl. Sci. 2019, 9, 3899 2 of 24 nanocomposites offer numerous opportunities in diverse applications, including nanocarriers, tissue engineering, antimicrobials, sensors, etc. These new groups of materials have gained significant research interest due to their novel properties, which are gained through the addition of nanofillers. Polymer nanocomposites have significant potential in disease theranostics, and nanotechnology brings great promise in cancer drug carriers [4].Chemotherapy implies the use of drugs and, besides the drugs, carriers. Common products used as carriers include synthetic polymers, biopolymers, and polymer nanocomposites.Some of the most useful drugs for chemotherapy are toxic chemicals able to inhibit the proliferation of cancer cells. The use of chemotherapeutic drugs has been in part hindered by their poor solubility in water, their short biological half-life, their lack of targeting ability, and the development of multidrug resistance [5]. In the last decades, nanoparticles have shown significant promise as an oncology treatment modality. Responsive polymers represent a promising class of nanoparticles that can trigger delivery through the exploitation of a specific stimuli. Response to a stimulus is one of the most basic processes found in living systems. A tutorial review highlighted the recent developments in polymer-based approaches to internally responsive nanoparticles for oncology [6].One important goal of medicine is to develop carriers that can selectively deliver anticancer drugs to tumor cells with no or minimal side effects in healthy cells [7,8].Polymers and their nanocomposites in different forms, such as micelles, hydrogels, polymersomes, and liposomes, have important potential in cancer diagnosis and treatment.Nanocomposites are popular in many areas due to properties such as their unique design capacity, eco-friendly nature, ...

show abstract

“…Savin et al reported a novel type of polymer nanocarriers, based on CS modified with poly(ethylene glycol) methacrylate, 8 in Scheme 1 [197]. Although PEG-grafted CS derivatives have been reported, in this study, CS-grafted poly(ethylene glycol) methacrylate (CS-g-PEGMA) was synthesized using a Michael addition, instead of radical grafting.…”

Section: Nanoparticles From Modified Chitosanmentioning

confidence: 92%

“…Scanning electron microscopy images of nanoparticles crosslinked with sodium tripolyphosphate (MA-7 and MA-8) or sodium sulfate (MA-G and MA-H). Reprinted from ref [197]…”

mentioning

confidence: 99%

Chitosan and its Derivatives for Ocular Delivery Formulations: Recent Advances and Developments

et al. 2020

View full text Add to dashboard Cite

Chitosan (CS) is a hemi-synthetic cationic linear polysaccharide produced by the deacetylation of chitin. CS is non-toxic, highly biocompatible, and biodegradable, and it has a low immunogenicity. Additionally, CS has inherent antibacterial properties and a mucoadhesive character and can disrupt epithelial tight junctions, thus acting as a permeability enhancer. As such, CS and its derivatives are well-suited for the challenging field of ocular drug delivery. In the present review article, we will discuss the properties of CS that contribute to its successful application in ocular delivery before reviewing the latest advances in the use of CS for the development of novel ophthalmic delivery systems. Colloidal nanocarriers (nanoparticles, micelles, liposomes) will be presented, followed by CS gels and lenses and ocular inserts. Finally, instances of CS coatings, aiming at conferring mucoadhesiveness to other matrixes, will be presented.

show abstract

Chitosan grafted-poly(ethylene glycol) methacrylate nanoparticles as carrier for controlled release of bevacizumab

Cited by 69 publications

References 47 publications

Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology

Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology

Polymers and Polymer Nanocomposites for Cancer Therapy

Chitosan and its Derivatives for Ocular Delivery Formulations: Recent Advances and Developments

Contact Info

Product

Resources

About